Skip to content

Released Mar 13, 2025, after the close

10-K filed Mar 13, 2025, 72 days after period end · 0000950170-25-038884

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$14.81Mderived−87.0% vs Q4 2023+73.8% vs Q3 2024
Net Income-$72.44MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$65,258,000N/M
Operating Cash Flowderived-$71,738,000N/M
Margins · derived
Operating margin-440.7%−478.6 pt vs Q4 2023
Net margin-489.2%−516.5 pt vs Q4 2023

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$14.81M$113.72M$8.63M$10.65M
Net Income-$72.44M$31.07M-$34.59M-$38.13M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR